# Apogee Therapeutics, Inc. (APGE) — merger/definitive [pending]
Source: SEC API (secapi.ai) · situation sit_2ea970d018cd41be8486 · retrieved 2026-08-12T06:55:44.764Z

## Overview
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in inflammatory and immunology markets, including for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, and other indications.

In June 2026, Apogee Therapeutics entered into a definitive agreement to be acquired by AbbVie Inc. for $135.11 per share in cash, representing a total equity value of approximately $10.9 billion. The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions including shareholder approval and receipt of required regulatory approvals. The acquisition is intended to strengthen AbbVie's immunology portfolio and advance development of Apogee's pipeline of therapies for inflammatory and immunological diseases.

## Terms
- Counterparty: AbbVie Inc. · Deal value: $10.90B · Consideration: cash · Price/share: $135.11

## Key dates
- Announced 2026-08-10 · Expected close 2026-09-30

## Timeline
- 2026-08-10 · 8-K (0001193125-26-341239): 8-K - Apogee Therapeutics, Inc. — *Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in inflammatory and immunology markets, including for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, and other indications.* In June 2026, Apogee Therapeutics entered into a definitive agreement to be acquired by AbbVie Inc. for $135.11 per share in cash, representing a total equity value of approximately $10.9 billion. The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions including shareholder approval and receipt of required regulatory approvals. The acquisition is intended to strengthen AbbVie's immunology portfolio and advance development of Apogee's pipeline of therapies for inflammatory and immunological diseases.
  https://www.sec.gov/Archives/edgar/data/1974640/0001193125-26-341239.txt

## Citations
- 0001193125-26-341239 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526341239